Assessing the Causal Relationship Between Plasma Proteins and Pulmonary Fibrosis: A Systematic Analysis Based on...

Area of Science:

• Genetics and Genomics
• Pulmonary Medicine
• Pharmacology

Background:

• Pulmonary fibrosis (PF) is a progressive lung disease with significant morbidity and mortality.
• Understanding the causal links between plasma proteins and PF is crucial for developing targeted therapies.
• Existing research highlights the role of plasma proteins but lacks systematic causal relationship studies.

Purpose of the Study:

• To identify potential drug targets for pulmonary fibrosis (PF) using a Mendelian randomization (MR) approach.
• To investigate the causal relationships between plasma proteins and the development and progression of PF.
• To evaluate the biological functions and pharmacological potential of identified targets.

Main Methods:

• Utilized Mendelian randomization (MR) with large-scale genome-wide association study (GWAS) data for plasma proteins (pQTL) and PF.
• Integrated enrichment analysis, protein-protein interaction (PPI) networks, drug prediction, molecular docking, and single-cell sequencing.
• Analyzed plasma protein data (n=35,559) and PF GWAS summary statistics (n=469,126).

Main Results:

• Identified 64 genetic loci significantly associated with PF occurrence.
• Revealed positive causal relationships between PF and genes including NPTX1, IL31, and CTSE.
• Discovered core genes (e.g., CDH1, CRP, VTN, COL1A1, MAPK8) involved in PF pathogenesis and identified potential drugs (sorafenib, vitamins C and E).

Conclusions:

• Successfully identified 64 potential drug targets for PF, with 10 core targets showing high promise for clinical development.
• The study provides valuable insights into PF molecular mechanisms, highlighting fibroblasts and alveolar type II cells.
• Findings pave the way for novel targeted therapies, potentially accelerating PF treatment development and reducing costs.